To provide the information your oncologist is not telling you or doesn't have the time to!
Explore a comprehensive range of insights and information within our ‘Varied Cancer Perspectives’ category. From melanoma to breast cancer, colorectal cancer to sarcoma, and beyond, this diverse collection delves into the multifaceted world of oncology. Gain a nuanced understanding of different cancer types, treatments, and the latest advancements in research. Whether you’re seeking knowledge on pediatric oncology, uveal melanoma, or desmoid tumors, our curated content provides a holistic view, offering valuable perspectives to empower and inform those navigating the complexities of cancer care. Join us on a journey through varied perspectives, ensuring a well-rounded understanding of the ever-evolving landscape of cancer.
Radiation therapy has long been a cornerstone in the treatment of various cancers, including gastric cancer, particularly for locally advanced or high-risk cases. However, the evolving landscape of gastric cancer management has raised questions about the necessity of adding preoperative chemoradiotherapy to standard perioperative chemotherapy. The recently published TOPGEAR trial sheds new light on this …
In the world of oncology, the old adage holds true: “When tumors are the rumors and cancer is possibly the answer, then tissue is the issue.” This highlights the critical role of biopsy in uncovering the true nature of suspicious lesions. Hepatic tumors, in particular, pose a diagnostic challenge because they encompass a broad spectrum …
Colon cancer treatments have long relied on surgery, chemotherapy, and radiation. However, recent breakthroughs in immunotherapy, particularly for mismatch repair–deficient (dMMR) tumors, are reshaping how certain high-risk cancers are treated. A recent study published in The New England Journal of Medicine provides encouraging data on the effectiveness of neoadjuvant immunotherapy for patients with locally advanced dMMR colon …
For patients with a specific type of breast cancer—hormone receptor-positive, HER2-negative—that also carries a PIK3CA mutation, a new combination treatment shows promising results. The treatment combines inavolisib, a targeted therapy, with palbociclib and fulvestrant, helping to significantly slow disease progression compared to standard treatment. This combination not only targets multiple cancer growth pathways but also …
Lung cancer remains one of the most common and deadly cancers worldwide. Smoking is responsible for approximately half of all lung cancer cases, making it the single most preventable cause of this disease. For individuals who have smoked for years, quitting can be difficult, and many turn to alternatives like electronic cigarettes (e-cigarettes) as a …
Anaplastic thyroid carcinoma (ATC) is one of the most aggressive and challenging types of thyroid cancer. Known for its rapid growth, resistance to conventional therapies, and poor prognosis, ATC has historically had limited treatment options. However, recent studies, including groundbreaking research by Dr. Maria Cabanillas and colleagues at MD Anderson Cancer Center, have highlighted the …
Multiple myeloma (MM) is a type of blood cancer originating in the plasma cells of the bone marrow, leading to an overproduction of abnormal plasma cells. This accumulation disrupts normal blood cell production and results in a range of complications, such as bone pain, anemia, kidney issues, and increased infection risk. Historically, treatment options for …
In a recent and courageous announcement, actor James Van Der Beek, known for roles in Dawson’s Creek and Varsity Blues, revealed his diagnosis of colorectal cancer. At age 47, Van Der Beek shared that he has been managing this diagnosis privately, taking steps towards treatment with the support of his family. While the specifics indicate …
Prostate cancer continues to pose a significant challenge for both patients and healthcare providers. In the realm of radiation therapy, the development of advanced techniques has transformed the landscape of treatment. A recent phase 3 trial comparing Stereotactic Body Radiotherapy (SBRT) to conventional radiotherapy for intermediate-risk prostate cancer provides new insights into how we can deliver effective …
The treatment landscape for advanced-stage classic Hodgkin’s lymphoma (cHL) is rapidly evolving. Traditionally, chemotherapy regimens such as AVD (doxorubicin, vinblastine, dacarbazine) or combinations including brentuximab vedotin have been used to manage this challenging disease. However, a groundbreaking phase 3 clinical trial (S1826) has introduced a promising new regimen—nivolumab (N+AVD)—that is proving to be superior in …